secwatch.observer — SEC 8-K summary
======================================

Issuer:     PDS Biotechnology Corp (PDSB)
CIK:        0001472091
Form:       8-K
Filed at:   2023-03-28T23:59:59+00:00
Accession:  0001140361-23-014118
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PDS Biotech FY2022 net loss $40.9M; cash to Q3 2024; PDS0101 shows 100% response in cervical cancer
--------------------------------------------------------------------------------

- Net loss for 2022 was $40.9M ($1.43/share) vs $16.9M ($0.66/share) in 2021; R&D expenses rose to $29.4M.
- Cash balance of $73.8M as of Dec 31, 2022; management expects funds into Q3 2024.
- FDA meeting supported registrational pathway for triple combo (PDS0101, PDS0301, ICI) in HPV+ cancers.
- IMMUNOCERV trial: 100% clinical response (9/9 >60% tumor shrinkage) in high-risk cervical cancer patients.
- Signed exclusive global license for PDS0301 from Merck KGaA for $10M ($5M cash + $5M in stock).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472091/000114036123014118/0001140361-23-014118-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472091/000114036123014118/brhc10050432_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-014118

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer